New combo therapy shows promise for rare lung cancer
NCT ID NCT03762018
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This study tested whether adding the immunotherapy drug atezolizumab to standard treatment (bevacizumab plus chemotherapy) helps people with advanced malignant pleural mesothelioma live longer. The trial involved 400 adults whose cancer could not be removed by surgery. Researchers measured overall survival and how long the cancer stayed under control. This is a disease-control study, not a cure, because ongoing treatment is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLEURAL MESOTHELIOMA MALIGNANT ADVANCED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AULSS2 Marca Trevigiana Treviso
Treviso, Italy
-
Addenbrooke's Hospital
Cambridge, United Kingdom
-
Alicante University Hospital ISABIAL
Alicante, Spain
-
CHU Liege
Liège, Belgium
-
CHUV
Lausanne, Switzerland
-
Caen- CHU
Caen, France
-
Clatterbridge Cancer Centre
Liverpool, United Kingdom
-
Complexo Hospitalario Universitario de Vigo
Vigo, Spain
-
Curie Cancer Center Paris
Paris, France
-
Ferdinando Cerciello
Bern, Switzerland
-
Fondazione IRCCS Istituto Nazionale die Tumori
Milan, Italy
-
Guy's and St Thomas' Hospital
London, United Kingdom
-
Hospital Nord
Marseille, France
-
Hospital Parc Tauli Sabadell
Sabadell, Spain
-
ICO Hospitalet
Barcelona, Spain
-
IRCCS Instituto Tumori Giovanni Paolo II
Bari, Italy
-
Instituto Europeo di Oncologia (IEO)
Milan, Italy
-
Istituto Oncologica della Svizzera Italiana
Bellinzona, Switzerland
-
Kantonsspital Aarau
Aarau, Switzerland
-
Kantonsspital Graubünden
Chur, Switzerland
-
Kantonsspital St. Gallen
Sankt Gallen, Switzerland
-
Kantonsspital Winterthur
Winterthur, Switzerland
-
Kent Oncology Centre
Maidstone, United Kingdom
-
Le Mans - CHG
Le Mans, France
-
Luzerner Kantonsspital
Lucerne, Switzerland
-
Lyon - Centre Léon Bérard
Lyon, France
-
Plymouth Hospitals NHS Trust
Plymouth, United Kingdom
-
Puerta de Hierro Hospital
Majadahonda, Spain
-
Royal Cornwall Hospital
Truro, United Kingdom
-
Royal Marsden Hospital (Fulham Road)
London, United Kingdom
-
Royal Marsden Hospital (Sutton)
London, United Kingdom
-
SS Antonio e Biagio e Cesare Arrigo Hospital
Alessandria, Italy
-
Toulouse - CHU
Toulouse, France
-
Tours - CHU
Tours, France
-
Unicancer - Institut Bergonie
Bordeaux, France
-
University Hospital Leuven
Leuven, Belgium
-
University Hospital of Turin
Turin, Italy
-
UniversitätSpital Zürich
Zurich, Switzerland
-
Vall Hebron University Hospital/Vall Hebron Institue Oncology
Barcelona, Spain
-
Virgen del Rocio
Seville, Spain
-
Weston Park Hospital
Sheffield, United Kingdom
-
Wythenshawe Hospital
Manchester, United Kingdom
Conditions
Explore the condition pages connected to this study.